📰 Alimera Sciences News
Page 4 - Alimera Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alimera Sciences. Real-time updates on events, politics, business and more.
October 29, 2023
StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research note published on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reissued a buy rating and set a $5.00 target price on shares of Alimera Sciences in a research note on Monday, […]
October 26, 2023
ALPHARETTA, Ga. (AP) — ALPHARETTA, Ga. (AP) — Alimera Sciences Inc. (ALIM) on Thursday reported a loss of $1.4 million in its third quarter.
October 26, 2023
Record net revenue and significant decrease in net loss highlight the quarter
October 26, 2023
Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion.
October 16, 2023
– Stuart Duty appointed to EyePoint's Board of Directors – – George Elston promoted to Executive Vice President – WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc.
October 16, 2023
16.10.2023 - Conference Call to be held the same day at 9:00am Eastern TimeATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and ...
October 10, 2023
The PALADIN study reported the intravitreal fluocinolone acetonide implant reduced the frequency of anti-VEGF injections in patients with diabetic macular edema out to 3 years.
October 6, 2023
FDA Commissioner Robert Califf said Thursday that misinformation, what he sees as one of the biggest issues facing his agency’s many jurisdictions, needs an equally expansive, overlapping approach.
October 6, 2023
Key Insights Institutions' substantial holdings in Alimera Sciences implies that they have significant influence over...
September 16, 2023
Caligan Partners LP (Trades, Portfolio), a New York-based investment firm, recently made a significant transaction in its portfolio. The firm reduced its stake in Alimera Sciences Inc, a commercial-stage pharmaceutical company. On September 14, 2023, Caligan Partners LP (Trades, Portfolio) reduced its holdings in Alimera Sciences Inc by 800,000 shares, representing a 4.54% change in the firm's portfolio.